At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 106 enrolled
Drug / intervention
LY2189102 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Randomized, Double-blind, Placebo Controlled, Parallel Design Study in Patients With Type 2 Diabetes Mellitus Who Are Stable on Diet and Exercise, With or Without Metformin Monotherapy.
In Brief
A Phase 2 clinical trial evaluating LY2189102 and Placebo for Type 2 Diabetes. Completed, enrolled 106 participants across 18 sites.
Detailed Summary
Study to evaluate the safety, tolerability and efficacy of LY2189102 in patients with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedJul 2009
Primary CompletionNov 2010
TodayJul 2026
First PostedJul 20, 2009
Enrollment StartJun 1, 2009
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 16.9 years ago
Interventions
LY2189102drug
Participants received 2 subcutaneous (SC) injections weekly for 12 weeks.
Placebodrug
Participants received 2 SC injections weekly for 12 weeks.